Quercetin-3-O-rutinoside, Rutoside, Sophorin, Vitamin P
Pharmacological Mechanism
Rutinoside (rhamnose-glucose) of quercetin. Cannot be absorbed intact — requires colonic microbial α-rhamnosidase to liberate quercetin-3-glucoside and then aglycone. Erlund 2000 showed Cmax of circulating quercetin after rutin is ~3× lower and Tmax 8× later than after equimolar quercetin aglycone, with terminal t½ ~11–28 h dominated by enterohepatic recycling of conjugates. All pharmacological activity in vivo is attributable to quercetin and its sulfate/glucuronide metabolites.
Half-Life & Elimination Curve (PO: 11h)
Plasma (PO)t½ Decay (11h)
0×t½0h100%(36.3 µg/L)
1×t½11h50%(18.1 µg/L)
2×t½22h25%(9.06 µg/L)
3×t½33h12.5%(4.53 µg/L)
4×t½44h6.3%(2.27 µg/L)
5×t½55h3.1%(1.13 µg/L)
Elimination t½11h (PO)
Rate Constant (ke)0.063 h⁻¹
Time to Peak (Tmax)9.97h
Est. Peak (Cmax)36.3 µg/L
Clearance (CL)6.18 L/h
97% Washout (5×t½)55h
Dosing Guidelines
Oral (PO): Typical 333 mg (Range: 250–500 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 2% · Volume of Distribution (Vd): 98 L · Absorption (ka): 0.15 h⁻¹ (t½ka ≈ 4.62h) [PMID 11151743]
Quercetin (synergistic): Rutin is the rhamnoglucoside prodrug of quercetin. Quercetin aglycone has higher and faster plasma exposure; rutin is slower-release via microbial deglycosylation.